明德生物收盘下跌1.32%，滚动市盈率120.74倍，总市值46.85亿元

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - For Q1 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company stood at 16.37% [1] Market Position - As of July 11, the company's stock closed at 20.15 yuan, down 1.32%, with a rolling price-to-earnings (PE) ratio of 120.74 times [1] - The total market capitalization of the company is 4.685 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 52.06 times, with a median of 37.22 times, placing Mingde Biological at the 108th position in the industry [1][2] Shareholder Information - As of June 30, 2025, the number of shareholders for Mingde Biological is 24,838, a decrease of 200 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]